How one hospital reduced pediatric epilepsy emergency visits, admissionsNationwide Children’s Hospital sees dramatic drop in ED visits and inpatient admissions for epilepsy patients with collaborative quality improvement project.
How physicians can guide seizure management in schoolsSeizures can be serious and scary in schools, but AAP guidelines say action plans outlining rescue medications and interventions can help.
Helping your epileptic patient
Helping your epileptic patientAn overview of anti-epileptic drugs and their use during pregnancy, as well as other perinatal considerations for women with seizure disorders.
FDA approves first 3D epilepsy drugFDA approved epilepsy drug levetiracetam (Spritam), the first FDA-approved drug that utilizes three-dimensional printing (3DP).
Anti-NMDA-receptor encephalitis: A review
Anti-NMDA-receptor encephalitis: A reviewIn 2005, a bizarre syndrome consisting of severe neuropsychiatric symptoms, seizures, loss of consciousness, and central hypoventilation was reported in 4 young women with ovarian teratoma (OT).
Antiepileptic drug can now be used in pediatric patientsFDA has expanded the indication for topiramate (Qudexy XR, Upsher-Smith Laboratories) extended-release capsules within the pediatric population.
DEA issues alert on fentanyl after overdosesThe United States Drug Enforcement Administration (DEA) on March 18 issued a nationwide alert about the dangers of fentanyl and fentanyl analogues/compounds.
FDA approves Banzel to treat seizures associated with LGS in pediatric patientsFDA has approved rufinamide (Banzel, Eisai) for the treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients.
Choking and cyanosis in an infant with sickle cell diseaseA 2-month-old African American girl who presented to the emergency department with 2 episodes of apnea or gasping respirations associated with feeds is admitted by your general inpatient pediatric service.
[BLOG] Pipeline advancement responsible for upturn in global pharma R&DThe world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year. According to our new Global Pharmaceutical Benchmark Report, Roche was the R&D spending leader, outlaying nearly $10 billion in 2013. Meanwhile, Novartis and Johnson & Johnson (J&J) increased their R&D spend the most between 2012 and 2013, with each adding around $500 million to their respective clinics. Novartis’ R&D spending grew by 5.6% to $9.8 billion, and J&J spent $8.2 billion, which was up by 6.8% from 2012.